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Abstract The World Marrow Donor Organization recom-
mends original granulocyte-colony stimulating factor (G-
CSF) for the mobilization of stem cells in healthy unrelated
hematopoietic stem cell donors.We report the comparison of a
biosimilar G-CSF (Zarzio) with two original G-CSFs
(filgrastim and lenograstim) in mobilization in unrelated do-
nors. We included data of 313 consecutive donors who were
mobilized during the period from October 2014 to
March 2016 at the Medical University of Warsaw. The prima-
ry endpoints of this study were the efficiency of CD34+ cell
mobilization to the circulation and results of the first aphere-
sis. The mean daily dose of G-CSF was 9.1 μg/kg for
lenograstim, 9.8 μg/kg for biosimilar filgrastim, and 9.3 μg/
kg for filgrastim (p < 0.001). The mean CD34+ cell number
per microliter in the blood before the first apheresis was 111
for lenograstim, 119 for biosimilar filgrastim, and 124 for
filgrastim (p = 0.354); the mean difference was even less sig-
nificant when comparing CD34+ number per dose of G-CSF
per kilogram (p = 0.787). Target doses of CD34+ cells were
reached with one apheresis in 87% donors mobilized with
lenograstim and in 93% donors mobilized with original and
biosimilar filgrastim (p = 0.005). The mobilized apheresis
outcomes (mean number of CD34+ cells/kg of donor collect-
ed during the first apheresis) was similar with lenograstim,
biosimilar filgrastim, and filgrastim: 6.2 × 106, 7.6 × 106,
and 7.3 × 106, respectively, p = 0.06. There was no mobiliza-
tion failure in any of the donors. Biosimilar G-CSF is as ef-
fective in the mobilization of hematopoietic stem cells in un-
related donors as original G-CSFs. Small and clinically irrel-
evant differences seen in the study can be attributed to differ-
ences in G-CSF dose and collection-related factors. Active
safety surveillance concurrent to clinical use and reporting to
donor outcome registry (e.g., EBMT donor outcome registry
or WMDA SEAR/SPEAR) might help to evaluate the possi-
ble short- and long-term complications of biosimilar G-CSF.
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Background
There are over 27 million registered unrelated hematopoietic
stem cell donors worldwide, as reported by the World Marrow
Donor Association (WMDA) [1]. The standard protocol of
mobilization in hematopoietic stem cell donors relies on two
original granulocyte-colony stimulating factors (G-CSF):
filgrastim and lenograstim. Those drugs have been evaluated
in clinical trials and neither showed advantages over another
[2]. However, studies conducted on healthy unrelated donors
are limited, as there was only one prospective [3] and two
retrospective studies comparing those drugs in this group [4, 5].
Recently, biosimilars of G-CSF have been introduced into
the stem cell mobilization protocols [6]. The experience with
mobilization in unrelated stem cell donors using biosimilar G-
CSF is very limited [7, 8]. The WMDA and the European
Society for Blood and Marrow Transplantation both argue
against the use of biosimilar G-CSF [9]. On the other hand,
the Working Party on Similar Biological (Biosimilar)
Medicinal Products of the European Medicines Agency
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supports expanding the use of the biosimilars that have to
provide sufficient human safety data before the approval [10].
In 2015, due to legal issues and changes in market availabil-
ity, the G-CSF used in mobilization of hematopoietic stem cells
in donors and patients at our institution has been first changed
from lenograstim to biosimilar filgrastim and later to original
filgrastim. As publications that compare biosimilars with both
original G-CSFs are limited, we decided to retrospectively an-
alyze the efficiency of mobilization with those three drugs in
healthy unrelated hematopoietic stem cell donors.
Material and methods
This study includedmedical data of 313 consecutive donors of
both genders aged between 19 and 55 years, who were mobi-
lized from October 2014 to March 2016. The sizes of the
donor groups mobilized with original G-CSFs were chosen
to resemble the size of the group mobilized with biosimilar
filgrastim.
The G-CSF formulations used in this study were
lenograstim—Granocyte (Chugai), biosimilar filgrastim—
Zarzio (Sandoz), and filgrastim—Neupogen (Amgen). We
did not report any serious adverse events (SAE) in the donors
during this study (including G-CSF injections, apheresis, and
postapheresis care).
Donation data were collected prospectively by our center
for scientific purposes. All donors gave written, informed con-
sent allowing the use of their anonymous medical records for
research purposes. All procedures were followed in accor-
dance with the ethical standards set by the responsible com-
mittee on human experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as revised in 2008.
The data for this study were collected frommedical records of
the donors that covered qualification, collection, and, in some
instances (when requested by donor center), donor follow-up.
The data chosen for the study included individual donor num-
ber, type of growth factor, dose of growth factor (prior to the
first apheresis and total dose), type of protocol, days of aphe-
resis, age, sex, weight, height, dose per kilogram, dose per
surface area, complete blood count at qualification, complete
preapheresis blood count, percent of CD34+ cells in blood,
number of CD34+ cells in blood, nucleated cell count in aphe-
resis product/products, percent of CD34+ cells in product/
products, CD34+ count (total product/products, per kg of pa-
tient weight), and complete blood count after apheresis.
Mobilization of stem cells
The donors were sent for evaluation and collection by different
donor registries. The final clearance was performed by apheresis
center—the donors who were qualified had no contraindications
according to the WMDA donor medical suitability
recommendations. The optimal daily dose for G-CSF was se-
lected based on the donor weight. For lenograstim, the target
dose was 7.5–10 μg/kg, and for filgrastim (original and
biosimilar), it was 7.5–10μg/kg. The daily dose has been round-
ed to the closest possible with 34-million-IU injections of
lenograstim or 30- and 48-million-IU injections of filgrastim.
The G-CSF was given 4 days before the donation with the daily
dose split into two injections—one given at 8 AM and the sec-
ond at 8 PM. The donors were trained on how to inject G-CSF
and those with no contraindications performed their injections
themselves. The access to a nurse who administered injections
was provided for donors who objected to self-injections.
The apheresis was performed with Spectra Optia cell sep-
arator (Terumo BCT, Lakewood, CO, USA). The separator
used software version 4 up to April 20, 2015 and version
11.2 throughout the rest of the studied period. All donors were
mobilized with MNC program prior to December 2015; later,
cMNC was performed in 30 out of 107 donors in the original
filgrastim group. Lenograstim was used until June 2015,
biosimilar filgrastim from June to October 2015, and
filgrastim was used afterwards. ACD-Awas used as coagula-
tion in a proportion of 0.9 AC.
The donors had one or two aphereses as needed to collect
the number of the CD34+ cells required by the transplant cen-
ter. The CD34+ cell count has been evaluated according to the
ISHAGE guidelines (dual-platform method) [11]. Statistical
analysis was performed withMedCalc Statistical Software ver-
sion 15.10 (MedCalc Software BVBA, Ostend, Belgium). In
all analyses, a p value of <0.05 was considered statistically
significant. The center evaluates CD34+ methodology by
performing CD34+ enumeration 6–8 times a year with a BD
Stem Cell Control Kit (BD Bioscences, San Jose, USA). There
were no reports of significant discrepancies in CD34+ cell
count from transplant centers in the studied period.
If one apheresis provided over 95% of requested stem cells,
the second apheresis was not performed. In the case of a sec-
ond apheresis, the time of the procedure (and the volume of
the product) was reduced in selected cases, so as not to mobi-
lize with excess. Mobilization failure was defined as collec-
tion of less than 2 × 106 of CD34+ cells per kilogram of body
weight of the recipient.
The primary endpoints of the study were the efficiency of
CD34+ cell mobilization to the circulation (measured as the
number of CD34+ cells per microliter prior to the initiation of
the first apheresis) and results of the first apheresis. The study
was not designed to analyze short- and long-term complica-
tions of G-CSF.
Results
Altogether, 313 consecutive healthy donors were included in
this study. One hundred twenty-one received lenograstim, 85
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biosimilar filgrastim, and 107 filgrastim as G-CSF in the mo-
bilization of hematopoietic stem cells. All three groups had
similar demographic data regarding sex distribution and me-
dian age; however, the group mobilized with biosimilar G-
CSF had higher body mass (+11% when compared to the
median weight in two other groups of patients, p = 0.02),
and the group mobilized with filgrastim had higher body mass
index than the other two groups, 25.6 vs 24.5 and 24.2
(p = 0.018) (Table 1).
The mean daily dose of G-CSF was 9.1 μg/kg for
lenograstim, 9.8 μg/kg for biosimilar filgrastim, and 9.3 μg/
kg for filgrastim (p < 0.001). The total mean dosage of G-CSF
to the first apheresis was different in all groups: 40.7 μg/kg for
lenograstim (29.0–52.4), 44 μg/kg for biosimilar filgrastim
(36–60), and 42 μg/kg for filgrastim (33–55)—the donors
who were mobilized with biosimilar filgrastim received mean
higher total doses of G-CSF (p = 0.014 vs filgrastim, p < 0.001
vs lenograstim). After four doses of G-CSF but before the last
dose of G-CSF prior to apheresis, the mean white blood cell
count was 43.7 g/l for lenograstim (33.8–52.5 interquartile
range), 45.2 g/l for biosimilar filgrastim (36.9–52.2 interquar-
tile range (IQR)), and 46.4 g/l for filgrastim (37.3–55.4 IQR)
(p = 0.246). The mean CD34+ cell number in the blood before
the initiation of apheresis was 111 cells/μl for lenograstim
(63–146 IQR), 119 cells/μl for biosimilar filgrastim (83–157
IQR), and 124 cells/μl for filgrastim (73–162 IQR)
(p = 0.354).
The mobilization with filgrastim and biosimilar filgrastim
was more efficient than that with lenograstim: 93% of donors
after one of the filgrastims needed one apheresis for sufficient
collection compared to 87% donors after lenograstim
(p = 0.005). The mean number of collected CD34+ cells × 106
per kilogram of donor: 6.2 for lenograstim, 7.6 for biosimilar
filgrastim, and 7.3 for filgrastim (p = 0.06). After correcting for
donorgender, themean number of collectedCD34+ cells × 106
per kilogram of recipient did not differ between the groups
(p = 0.129) but generally higher collections were reported in
men than in women (9.44 vs 6.3, p < 0.0001). Additionally,
gender had the same effect on collection with all three growth
factors (p = 0.847). There were no differences regarding the
number of collected CD34+ cells × 106 per kilogram of recip-
ient between donors when MNC or cMNC was used (7.5 vs
8.6, p = 0.334) and those who underwent aphereses using
different versions of cell separator software (p = 0.086).
There were no mobilization failures, with 100% of donors
mobilizing over 2 × 106 CD34+ cells/kg of recipient. Themean
Table 1 Basic data of the study population of unrelated donors
Lenograstim Biosimilar filgrastim Filgrastim p value
Number of donors in the group 121 85 107
Median age (interquartile range, years) 29 (23–34) 26 (22–33) 29 (24–35.5) 0.251
BMI (interquartile range) 24.5 (22.1–26.7) 24.2 (21.5–26.2) 25.6 (22.7–28.4) 0.018
Gender 71 males/50 females 60 males/25 females 70males/37 females 0.107
Median weight of the donor (interquartile range, kg) 74 (63.5–85) 82 (63.5–85) 74 (69–90) 0.0262
Mean daily dose of G-CSF (interquartile range, μg/kg of donor) 9.1 (8.3–9.9) 9.8 (9.0–10.4) 9.3 (8.7–10.0) <0.001
Table 2 The most important differences between G-CSFs in mobilization of unrelated hematopoietic stem cells donors
Lenograstim Biosimilar filgrastim Filgrastim p value
Mean preapheresis white blood cell count (interquartile range, g/l) 43.7 (33.8–52.5) 45.2 (36.9–52.2) 46.4 (37.3–55.4) 0.246
Mean preapheresis erythrocytes count (interquartile range, g/l) 4.70 (4.38–4.95) 4.76 (4.44–5.09) 4.79 (4.55–5.06) 0.193
Mean preapheresis thrombocytes count (interquartile range, g/l) 237 (198–267) 236 (196–276) 250 (215–285) 0.126
Mean preapheresis CD34+ count (interquartile range, cells/μl) 111 (63–136) 119 (83–157) 124 (73–162) 0.354
Mean number of CD34+ cells collected from first apheresis
(interquartile range, ×106/kg of recipient)
7.5 (4.5–9.2) 8.3 (5.2–9.8) 9.4 (5.5–11.0) 0.06
Mean number of CD34+ cells collected from all apheresesa
(interquartile range, ×106/kg of recipient)
7.7 (4.7–9.2) 8.5 (5.7–9.8) 9.4 (5.5–11.0) 0.085
Growth factor efficiency (interquartile range, mean number of
CD34+ cells from first apheresis per kg per daily G-CSF dose in μg/kg)
0.68 (0.42–0.87) 0.75 (0.52–0.95) 0.77 (0.57–0.97) 0.074
Percentage of donors that needed one apheresis for collection (%) 87 93 93 0.005
Mean postapheresis white blood cell count (interquartile range, g/l) 40.1 (32.4–46.1) 46.2 (39.5–51.0) 46.24 (38.0–55.6) <0.001
Mean postapheresis erythrocytes count (interquartile range, g/l) 4.41 (4.05–4.70) 4.52 (4.18–4.83) 4.58 (4.28–4.84) 0.013
Mean postapheresis thrombocytes count (interquartile range, g/l) 147 (118–169) 152 (122–178) 167 (138–193) <0.001
aAll aphereses—one or maximum two aphereses in a donor
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difference in the total number of collected CD34+ cells × 106
per kilogram of recipient between different G-CSFs was also
not statically significant: 7.7 for lenograstim, 8.5 for biosimilar
filgrastim, and 9.4 for filgrastim (p = 0.085). The most impor-
tant comparisons between mobilization with lenograstim,
biosimilar filgrastim, and filgrastim are summarized in Table 2.
Discussion
The biosimilar G-CSF is not used as standard in the mobili-
zation of hematopoietic stem cells in unrelated donors. Due to
the unlikely coincidence of issues with the availability of the
drugs on the market, we were able to retrospectively compare
the two original G-CSFs (lenograstim and filgrastim) with
biosimilar filgrastim. The primary endpoints of our study, mo-
bilization of CD34+ into circulation and results of the first
apheresis, have shown no statistically significant differences
between original and biosimilar drugs.We observed almost no
clinically relevant difference between the drugs—the number
of donors needing one apheresis is similar in three groups—
with differences related possibly to slight differences in dose,
sex distribution, and procedure of cell separation.
Previous studies have also shown differences between
lenograstim and filgrastim—however, in favor of lenograstim.
Ings et al. [5] have shown that lenograstim had higher CD34+
cell collections—but they have failed to show data on actual
G-CSF doses in studied groups and their groups had different
sex distributions. Higher efficiency of lenograstim was also
reported by Bertani and colleagues [12]. The data in both of
those studies could also be influenced by the use of different
cell separators and their software, as it took 10 [5] or 18 [12]
years to collect patient data. Similar results were also reported
in a prospective study by Fischer and colleagues [3]—again,
reporting roughly 10% higher stem cell collection yields using
lenograstim, with very similar fist apheresis collection num-
bers to those reported in this publication. The actual dose of G-
CSF in that study was almost 20% higher than that applied to
the patients in our analysis—most likely influencing the ob-
served differences. In our study, a small but statistically sig-
nificant dose differences in lenograstim and filgrastims could
have influenced the final CD34+ cell yield. The results of this
study show that biosimilar filgrastim performs almost identi-
cally to original products. The ongoing prospective study will
provide more data on this topic—most importantly assessing
the differences in side effects between the drugs [8].
The biggest limitation of this study was the inability to
assess the short- and long-term side effects of the studied
drugs. On the other hand, the short-term side effects of the
drugs will likely not differ significantly [8]. We also do not
report cell separation data and only focus on preapheresis data
and product data. There is a possibility that the outcomes
could have been influenced by differences in cell separation
which is beyond the scope of the study.
Conclusion
Our data provide positive evidence for the use of biosimilar G-
CSF in healthy unrelated hematopoietic stem cell donors. It is
shown that the biosimilar G-CSF does not differ from the
original growth factors when the mobilization of the CD34+
positive cells is analyzed. We still need to wait for the results
of long-term observations of the donors after biosimilar G-
CSF before we can recommend its use as standard in the
mobilization of hematopoietic stem cells in healthy unrelated
donors.
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